CD7 and acute lymphoblastic leukemia: In a phase I clinical trial of autologous CD7 CAR-T cells for R/R T-ALL/LBL patients (NCT04004637), 87.5% of participants achieved CR at three months postinfusion, with the majority experiencing only minor side effects.